NCT07343115招募中不适用
Familial Systemic Scleroderma
University Hospital, Strasbourg, France1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年9月2日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Description of the clinical characteristics of patients with familial systemic scleroderma
研究概览
简要总结
Studying familial forms of systemic scleroderma offers several advantages:
- To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms);
- To identify potential molecular markers predictive of disease progression;
- To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult subjects (≥ 18 years of age)
- •Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
- •At least one first-degree relative with systemic scleroderma meeting the same criteria
排除标准
- •- Subject who has expressed opposition to participating in the study
结局指标
主要结局
Description of the clinical characteristics of patients with familial systemic scleroderma
时间窗: Up to 12 months
The clinical presentation describes how the disease manifests in patients: the symptoms, their severity, and their progression.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Scleroderma RegistrySclerodermaSystemic SclerosisNCT00074568National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)5,000
Unknown
2 期
High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic SclerosisScleroderma, DiffuseNCT00428883Università Politecnica delle Marche45
已完成
2 期
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic SclerosisScleroderma, DiffuseDiffuse Cutaneous Systemic SclerosisNCT02503644Inventiva Pharma145
已完成
1 期
IL1-TRAP, Rilonacept, in Systemic SclerosisSclerodermaDiffuse SclerodermaDiffuse Systemic SclerosisSystemic SclerosisNCT01538719Boston University24
已完成
不适用
Systemic Sclerosis' Relatives ReflexCaregiversSystemic SclerosisNCT04917146Assistance Publique - Hôpitaux de Paris50